Renata Duchnowska
Overview
Explore the profile of Renata Duchnowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
824
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zok J, Bienkowski M, Radecka B, Kuchar A, Borowiec S, Streb J, et al.
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):297-303.
PMID: 39935752
Introduction: The BRAF mutation is found in 6-11% of metastatic colo-rectal cancer (mCRC) patients. According to international guidelines for BRAF-mutated mCRC, the triplet chemotherapy FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan)...
2.
Popeda M, Zok J, Tomasik B, Duchnowska R, Bienkowski M
Int J Colorectal Dis
. 2025 Jan;
40(1):21.
PMID: 39836241
Purpose: Liver and lung metastases demonstrate distinct biological, particularly immunological, characteristics. We investigated whether preoperative complete blood count (CBC) parameters, which may reflect the immune system condition, predict early dissemination...
3.
Jarzab M, Litwiniuk M, Innis P, Lacko A, Enderle G, Czartoryska-Arlukowicz B, et al.
Contemp Oncol (Pozn)
. 2024 Nov;
28(3):245-252.
PMID: 39512534
Introduction: Breast cancer (BC) is among the most frequently diagnosed malignant tumours in females. The optimal treatment of early HR+, HER2-, and lymph node-negative (N0) BC remains challenging. Since individual...
4.
Gorczynski A, Miszewski K, Gager Y, Koch S, Potschke J, Ugrinovski D, et al.
Cancer Biomark
. 2023 Jul;
38(1):17-26.
PMID: 37522200
Background: ALK receptor tyrosine kinase (ALK) aberrations have an established role in pathogenesis of many neoplasms, but their clinical significance in high grade serous ovarian carcinoma (HGSOC) is unclear. Objective:...
5.
Khan I, Gril B, Paranjape A, Robinson C, Difilippantonio S, Biernat W, et al.
Mol Cancer Ther
. 2023 Mar;
22(5):646-658.
PMID: 36912773
Advances in drug treatments for brain metastases of breast cancer have improved progression-free survival but new, more efficacious strategies are needed. Most chemotherapeutic drugs infiltrate brain metastases by moving between...
6.
Tomasik B, Bienkowski M, Gorska Z, Gutowska K, Kumiega P, Jassem J, et al.
Cancer Treat Rev
. 2023 Feb;
114:102521.
PMID: 36736124
Brain metastases (BM) are a common and devastating manifestation of breast cancer (BC). BM are particularly frequent in the HER2-positive and triple-negative breast cancer phenotypes and usually occur following the...
7.
Nicos M, Harbers L, Patrucco E, Kramer-Drauberg M, Zhang X, Voena C, et al.
JTO Clin Res Rep
. 2022 Dec;
3(12):100435.
PMID: 36561283
Introduction: Brain metastases (BM) severely affect the prognosis and quality of life of patients with NSCLC. Recently, molecularly targeted agents were found to have promising activity against BM in patients...
8.
Duchnowska R, Supernat A, Peksa R, Lukasiewicz M, Stokowy T, Ronen R, et al.
Sci Rep
. 2022 Nov;
12(1):20537.
PMID: 36446793
Brain metastases (BMs) in ovarian cancer (OC) are a rare event. BMs occur most frequently in high-grade serous (HGS) OC. The molecular features of BMs in HGSOC are poorly understood....
9.
Kufel-Grabowska J, Niwinska A, Radecka B, Ali S, Mandat T, Duchnowska R
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267407
Background: Determining the proper therapy is challenging in breast cancer (BC) patients with brain metastases (BM) due to the variability of an individual's prognosis and the variety of treatment options...
10.
Niwinska A, Pogoda K, Jagiello-Gruszfeld A, Duchnowska R
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205723
Brain metastases are detected in 5% of patients with breast cancer at diagnosis. The rate of brain metastases is higher in HER2-positive and triple-negative breast cancer patients (TNBC). In patients...